Estradiol/raloxifene

Estradiol/raloxifene (E2/RLX) is a tissue-selective estrogen complex (TSEC) which was studied for potential use in menopausal hormone therapy but was never marketed.[2][1][3][4][5]

Estradiol/raloxifene
Combination of
EstradiolEstrogen
RaloxifeneSelective estrogen receptor modulator
Clinical data
Other namesE2/RLX; Raloxifene/estradiol; RLX/E2
Routes of
administration		By mouth; Transdermal administration; Vaginal administration[1]
Legal status
Legal status

See also

References
  1. Pickar JH, Boucher M, Morgenstern D (September 2018). "Tissue selective estrogen complex (TSEC): a review". Menopause. 25 (9): 1033–1045. doi:10.1097/GME.0000000000001095. PMC 6110370. PMID 29533367.
  2. Komm BS (December 2008). "A new approach to menopausal therapy: the tissue selective estrogen complex". Reprod Sci. 15 (10): 984–92. doi:10.1177/1933719108325759. PMID 19088368. S2CID 11875637.
  3. Komm BS, Mirkin S, Jenkins SN (November 2014). "Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss". Steroids. 90: 71–81. doi:10.1016/j.steroids.2014.06.004. PMID 24929044. S2CID 6342960.
  4. Archer DF (July 2010). "Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms". Drugs Aging. 27 (7): 533–44. doi:10.2165/11316000-000000000-00000. PMID 20583848. S2CID 23784261.
  5. Pinkerton JV, Conner EA (April 2019). "Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators". Climacteric. 22 (2): 140–147. doi:10.1080/13697137.2019.1568403. PMID 30895900. S2CID 84842485.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.